Replies to post #173426 on Biotech Values

[DewDiligence]

TEVA/MNTA/MYL…guess the main strategy [wrt thrice-weekly Copaxone] is statements like the one made by Prof. Khan.

I’m not sure what you’re referring to—please elaborate.

[DewDiligence]

Teva’s thrice-weekly Copaxone is priced at about a 10% discount to regular (daily) Copaxone, according to MNTA’s CFO, Rick Shea on today's Leerink webcast. (This differs from the prior unconfirmed report that the discount was 2%.)